Cited by 1,858HER2/EGFR in Cancer ResearchPI3K/AKT/mTOR signaling in cancerBreast Cancer Treatment Studies

The DOI matches its Crossref record; 65 of the 70 references it cites were found in a registry or an index.

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Open access

Nagata, Yoichi, Lan, Keng-Hsueh, Zhou, Xiaoyan, Tan, Ming, Esteva, Francisco J., Sahin, Aysegul A., Klos, Kristine S., Li, Ping, Monia, Brett P., Nguyen, Nina T., Hortobagyi, Gabriel N., Hung, Mien-Chie, Yu, Dihua·2004·Cancer Cell

DOI 10.1016/j.ccr.2004.06.022

Open this paper in CoChat — free account Open PDF

Abstract

The ErbB2-targeting antibody, trastuzumab (Herceptin), has remarkable therapeutic efficacy in certain patients with ErbB2-overexpressing tumors. The overall trastuzumab response rate, however, is limited and what determines trastuzumab response is poorly understood. Here we report that PTEN activation contributes to trastuzumab's antitumor activity. Trastuzumab treatment quickly increased PTEN membrane localization and phosphatase activity by reducing PTEN tyrosine phosphorylation via Src inhibition. Reducing PTEN in breast cancer cells by antisense oligonucleotides conferred trastuzumab resistance in vitro and in vivo. Patients with PTEN-deficient breast cancers had significantly poorer responses to trastuzumab-based therapy than those with normal PTEN. Thus, PTEN deficiency is a powerful predictor for trastuzumab resistance. Additionally, PI3K inhibitors rescued PTEN loss-induced trastuzumab resistance, suggesting that PI3K-targeting therapies could overcome this resistance.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2004.06.022

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway
Cantley, L. C., & Neel, B. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4240 · Cited by 2,018
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
Cho, H., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., & Leahy, D. J. (2003) · Nature · doi:10.1038/nature01392 · Cited by 1,637
The Multiple Roles of PTEN in Tumor Suppression
Di Cristofano, A., & Pandolfi, P. P. (2000) · Cell · doi:10.1016/s0092-8674(00)80674-1 · Cited by 1,182
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D. D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 886

Flagged first, then by citations

Show all 70 references

5 of the 70 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Petit, 1997, Neutralizing antibodies against epidermal growth factor and ErbB2/neu receptor tyrosine kinase down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo, Am. J. Pathol., 151, 1523

Sorted by citations

Items 401–500 of 1,001

The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition
Shi, J., Li, F., Yao, X., Mou, T., Xu, Z., Han, Z., Chen, S., Li, W., Yu, J., Qi, X., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0204-5 · Cited by 88
The Mucin Muc4 Potentiates Neuregulin Signaling by Increasing the Cell-surface Populations of ErbB2 and ErbB3
Funes, M., Miller, J. K., Lai, C., Carraway, K. L., & Sweeney, C. A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603225200 · Cited by 88
Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer
Nahta, R. (2012) · ISRN Oncology · doi:10.5402/2012/428062 · Cited by 93
HER2 as a target for breast cancer therapy
Tagliabue, E., Balsari, A., Campiglio, M., & Pupa, S. M. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712591003689972 · Cited by 87
Trastuzumab-Resistant Breast Cancer Cells Remain Sensitive to the Auger Electron–Emitting Radiotherapeutic Agent 111In-NLS-Trastuzumab and Are Radiosensitized by Methotrexate
Costantini, D. L., Bateman, K. J., McLarty, K., Vallis, K. A., & Reilly, R. M. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.051771 · Cited by 88
Targeted therapies in breast cancer: Where are we now?
Cosimo, S. D., & Baselga, J. M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.09.026 · Cited by 89
PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition
Cretella, D., Digiacomo, G., Giovannetti, E., & Cavazzoni, A. (2019) · Cancers · doi:10.3390/cancers11091318 · Cited by 88
Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs
Dı́az-Rodrı́guez, E., Gandullo‐Sánchez, L., Ocaña, A., & Pandiella, A. (2021) · Cancers · doi:10.3390/cancers14010154 · Cited by 87
Antitumor activity of HER-2 inhibitors
Rabindran, S. K. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.11.015 · Cited by 87
ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective
Saxena, R., & Dwivedi, A. (2010) · Medicinal Research Reviews · doi:10.1002/med.20209 · Cited by 88
PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and Target
Salvatore, L., Calegari, M. A., Loupakis, F., Fassan, M., Stefano, B. D., Bensi, M., Bria, E., & Tortora, G. (2019) · Cancers · doi:10.3390/cancers11111765 · Cited by 86
Anti-HER agents in gastric cancer: from bench to bedside
Fornaro, L., Lucchesi, M., Caparello, C., Vasile, E., Caponi, S., Ginocchi, L., Masi, G., & Falcone, A. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.81 · Cited by 84
PI3K/mTORC1 activation in hamartoma syndromes: Therapeutic prospects
Krymskaya, V. P., & Goncharova, E. A. (2009) · Cell Cycle · doi:10.4161/cc.8.3.7555 · Cited by 84
Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Kalous, O., Conklin, D. F., Desai, A. J., O’Brien, N. A., Ginther, C., Anderson, L. A., Cohen, D. J., Britten, C. D., Taylor, I. W., Christensen, J. G., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0730 · Cited by 84
Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science
Hochberg, F. H., Atai, N. A., Gonda, D. D., Hughes, M. S., Mawejje, B., Balaj, L., & Carter, R. S. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2014.905202 · Cited by 86
An Epigenetic Pathway Regulates Sensitivity of Breast Cancer Cells to HER2 Inhibition via FOXO/c-Myc Axis
Matkar, S. S., Sharma, P., Gao, S.-B., Gurung, B., Katona, B. W., Liao, J., Muhammad, A. B., Kong, X.-C., Wang, L., Jin, G., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.005 · Cited by 87
Herceptin Sensitizes ErbB2–Overexpressing Cells to Apoptosis by Reducing Antiapoptotic Mcl-1 Expression
Henson, E. S., Hu, X., & Gibson, S. B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0754 · Cited by 85
14-3-3ζ Down-regulates p53 in Mammary Epithelial Cells and Confers Luminal Filling
Danes, C. G., Wyszomierski, S. L., Lü, J., Neal, C. L., Yang, W., & Yu, D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3177 · Cited by 84
EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance
Dua, R., Zhang, J., Nhonthachit, P., Penuel, E. M., Petropoulos, C., & Parry, G. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0592-x · Cited by 90
Insulin-Like Growth Factor Binding Protein-2 Is a Novel Therapeutic Target Associated with Breast Cancer
So, A., Levitt, R. J., Eigl, B. J., Fazli, L., Muramaki, M., Leung, S., Cheang, M. C. U., Nielsen, T. O., Gleave, M. E., & Pollak, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0408 · Cited by 84
Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments
Barros, F., Powe, D. G., Ellis, I. O., & Green, A. R. (2010) · Histopathology · doi:10.1111/j.1365-2559.2010.03494.x · Cited by 83
Insulin-Like Growth Factor (IGF) Binding Protein 2 Functions Coordinately with Receptor Protein Tyrosine Phosphatase β and the IGF-I Receptor To Regulate IGF-I-Stimulated Signaling
Shen, X., Xi, G., Maile, L. A., Wai, C., Rosen, C. J., & Clemmons, D. R. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.01011-12 · Cited by 83
The role of oncomirs in the pathogenesis and treatment of breast cancer
Hemmatzadeh, M., Mohammadi, H., Jadidi‐Niaragh, F., Asghari, F., & Yousefi, M. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.01.026 · Cited by 85
Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer
Luo, L., Zhang, Z., Qiu, N., Ling, L., Jia, X., Song, Y., Li, H., Li, J., Lyu, H., Liu, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23052-9 · Cited by 81
Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs
Henjes, F., Bender, C., von der Heyde, S., Braun, L., Mannsperger, H., Schmidt, C., Wiemann, S., Hasmann, M., Aulmann, S., Beißbarth, T., et al. (2012) · Oncogenesis · doi:10.1038/oncsis.2012.16 · Cited by 82
Everolimus in the Treatment of Metastatic Breast Cancer
Royce, M., & Osman, D. I. (2015) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s29268 · Cited by 86
Overcoming resistance to tyrosine kinase inhibitors: Lessons learned from cancer cells treated with EGFR antagonists
Rexer, B. N., Engelman, J. A., & Arteaga, C. L. (2009) · Cell Cycle · doi:10.4161/cc.8.1.7324 · Cited by 84
Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells
Menéndez, J. A., Vellón, L., & Lupu, R. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2004.09.027 · Cited by 82
The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer
Diver, E., Foster, R., Rueda, B. R., & Growdon, W. B. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0149 · Cited by 83
HER2-targeted gold nanoparticles potentially overcome resistance to trastuzumab in gastric cancer
Kubota, T., Kuroda, S., Kanaya, N., Morihiro, T., Aoyama, K., Kakiuchi, Y., Kikuchi, S., Nishizaki, M., Kagawa, S., Tazawa, H., et al. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.05.019 · Cited by 82
Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy
Sokolosky, M. L., Stadelman, K. M., Chappell, W. H., Abrams, S. L., Martelli, A. M., Stivala, F., Libra, M., Nicoletti, F., Дробот, Л. Б., Franklin, R. A., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.302 · Cited by 83
Targeting Intracellular Signaling Pathways as a Novel Strategy in Melanoma Therapeutics
Smalley, K. S. M., & Herlyn, M. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1339.005 · Cited by 80
Trastuzumab Emtansine: The First Targeted Chemotherapy for Treatment of Breast Cancer
Peddi, P. F., & Hurvitz, S. A. (2013) · Future Oncology · doi:10.2217/fon.13.7 · Cited by 82
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells
Rexer, B. N., Chanthaphaychith, S., Dahlman, K. B., & Arteaga, C. L. (2014) · Breast Cancer Research · doi:10.1186/bcr3601 · Cited by 80
Solubility enhancement and targeted delivery of a potent anticancer flavonoid analogue to cancer cells using ligand decorated dendrimer nano-architectures
Luong, D., Kesharwani, P., Killinger, B. A., Moszczyńska, A., Sarkar, F. H., Padhyé, S., Rishi, A. K., & Iyer, A. K. (2016) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2016.08.061 · Cited by 80
The interface between phosphatidylinositol transfer protein function and phosphoinositide signaling in higher eukaryotes
Grabon, A., Bankaitis, V. A., & McDermott, M. I. (2018) · Journal of Lipid Research · doi:10.1194/jlr.r089730 · Cited by 77
Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
Mariani, G., Fasolo, A., Benedictis, E. D., & Gianni, L. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1298 · Cited by 80
RGS16 Inhibits Breast Cancer Cell Growth by Mitigating Phosphatidylinositol 3-Kinase Signaling
Liang, G., Bansal, G., Xie, Z., & Druey, K. M. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.028407 · Cited by 80
Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis
Schade, A. E., Powers, J. J., Włodarski, M. W., & Maciejewski, J. P. (2006) · Blood · doi:10.1182/blood-2005-08-3076 · Cited by 81
PTPH1 Dephosphorylates and Cooperates with p38γ MAPK to Increase Ras Oncogenesis through PDZ-Mediated Interaction
Hou, S.-W., Zhi, H.-Y., Pohl, N. M., Loesch, M., Qi, X.-M., Li, R.-S., Basir, Z., & Chen, G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3229 · Cited by 81
Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives
Criscitiello, C., André, F., Thompson, A. M., Laurentiis, M. D., Espósito, A., Gelao, L., Fumagalli, L. A. M., Locatelli, M., Minchella, I., Orsi, F., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3630 · Cited by 80
Overcoming Trastuzumab Resistance in HER2-Overexpressing Breast Cancer Cells by Using a Novel Celecoxib-Derived Phosphoinositide-Dependent Kinase-1 Inhibitor
Tseng, P., Wang, Y.-C., Weng, S., Weng, J., Chen, C.-S., Brueggemeier, R. W., Shapiro, C. L., Chen, C., Dunn, S. E., Pollak, M., et al. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.023911 · Cited by 80
Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer
Ahn, D. H., Li, J., Wei, L., Doyle, A., Marshall, J. L., Schaaf, L. J., Phelps, M. A., Villalona-Calero, M. A., & Bekaii‐Saab, T. (2015) · Scientific Reports · doi:10.1038/srep12122 · Cited by 80
An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients
Piro, G., Carbone, C., Cataldo, I., Nicolantonio, F. D., Giacopuzzi, S., Aprile, G., Simionato, F., Boschi, F., Zanotto, M., Mina, M. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0178 · Cited by 84
Valproic Acid and Breast Cancer: State of the Art in 2021
Wawruszak, A., Hałasa, M., Okoń, E., Kukula-Koch, W. A., & Stepulak, A. (2021) · Cancers · doi:10.3390/cancers13143409 · Cited by 78
Phase II trial of temsirolimus in patients with metastatic breast cancer
Fleming, G. F., Ma, C. X., Huo, D., Sattar, H. A., Tretiakova, M., Li, L., Hahn, O. M., Olopade, F. O., Nanda, R., Hoffman, P. C., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1910-7 · Cited by 78
Fulvestrant-Induced Cell Death and Proteasomal Degradation of Estrogen Receptor α Protein in MCF-7 Cells Require the CSK c-Src Tyrosine Kinase
Yeh, W., Shioda, K., Coser, K. R., Rivizzigno, D., McSweeney, K. R., & Shioda, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060889 · Cited by 78
Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference
Tan, D. S. W., Gerlinger, M., Teh, B. T., & Swanton, C. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.03.019 · Cited by 79
Imaging and Oncologic Drug Development
El‐Deiry, W. S., Sigman, C. C., & Kelloff, G. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5623 · Cited by 78
Whole genome DNA methylation signature of HER2-positive breast cancer
Lindqvist, B. M., Wingren, S., Motlagh, P. B., & Nilsson, T. (2014) · Epigenetics · doi:10.4161/epi.29632 · Cited by 81
Advances in the Management of HER2-positive Advanced Gastric and Gastroesophageal Junction Cancer
Bang, Y. (2012) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3182557307 · Cited by 78
HER2 expression patterns in paired primary and metastatic endometrial cancer lesions
Halle, M. K., Tangen, I. L., Berg, H. F., Høivik, E. A., Mauland, K. K., Kusonmano, K., Berg, A., Hurtado, A., Kalland, K., Oyan, A. M., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.422 · Cited by 78
Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer
Wong, A. L., & Lee, S. C. (2012) · International Journal of Breast Cancer · doi:10.1155/2012/415170 · Cited by 77
Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression
Li, G., Zhao, L., Li, W., Fan, K., Qian, W., Hou, S., Wang, H., Dai, J., Wei, H., & Guo, Y. (2014) · Oncotarget · doi:10.18632/oncotarget.2135 · Cited by 77
Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression
Inoue, M., Mimura, K., Izawa, S., Shiraishi, K., Inoue, A., Shiba, S., Watanabe, M., Maruyama, T., Kawaguchi, Y., Inoue, S., et al. (2012) · Oncoimmunology · doi:10.4161/onci.21056 · Cited by 80
Current Status of Anti–Human Epidermal Growth Factor Receptor 2 Therapies: Predicting and Overcoming Herceptin Resistance
Chung, A. P., Cui, X., Audeh, W., & Giuliano, A. E. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.04.001 · Cited by 77
Targeting the gatekeeper residue in phosphoinositide 3-kinases
Alaimo, P. J., Knight, Z. A., & Shokat, K. M. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.02.021 · Cited by 77
Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
Yan, Y., Serra, V., Prudkin, L., Scaltriti, M., Murli, S., Rodríguez, O., Guzmán, M., Sampath, D., Nannini, M., Xiao, Y., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0978 · Cited by 77
Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: A systematic review
Madarnas, Y., Trudeau, M., Franek, J. A., McCready, D. R., Pritchard, K. I., & Messersmith, H. J. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.03.013 · Cited by 77
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
Hurvitz, S. A., Dalenc, F., Campone, M., O’Regan, R. M., Tjan-Heijnen, V. C., Gligorov, J., Llombart, A., Jhangiani, H., Mirshahidi, H. R., Tan-Chiu, E., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2689-5 · Cited by 76
Primary trastuzumab resistance: new tricks for an old drug
Wilken, J. A., & Maihle, N. J. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05782.x · Cited by 77
Integrating Molecular Mechanisms and Clinical Evidence in the Management of Trastuzumab Resistant or Refractory HER-2+ Metastatic Breast Cancer
Wong, H., Leung, R. C.-Y., Kwong, A., Chiu, J. W. Y., Liang, R. H.-S., Swanton, C., & Yau, T. C. C. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0165 · Cited by 76
Her2-Targeted Therapies in Non–Small Cell Lung Cancer
Swanton, C., Futreal, A., & Eisen, T. G. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0115 · Cited by 76
The PTEN tumor suppressor gene and its role in lymphoma pathogenesis
Wang, X., Huang, H., & Young, K. H. (2015) · Aging · doi:10.18632/aging.100855 · Cited by 78
HER2-positive breast cancer is lost in translation: time for patient-centered research
Gingras, I., Gebhart, G., de Azambuja, E., & Piccart, M. J. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.96 · Cited by 74
Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers
Sun, B., Mason, S., Wilson, R. C., Hazard, E. S., Wang, Y., Fang, R., Wang, Q., Yeh, E. S., Yang, M., Roberts, T. M., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0953-9 · Cited by 78
Mechanisms of Trastuzumab Resistance and Their Clinical Implications
Lan, K., Lu, C., & Yu, D. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1339.026 · Cited by 75
PTEN Deficiency in a Luminal ErbB-2 Mouse Model Results in Dramatic Acceleration of Mammary Tumorigenesis and Metastasis
Schade, B., Rao, T., Dourdin, N., Lesurf, R., Hallett, M. T., Cardiff, R. D., & Muller, W. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.018937 · Cited by 77
Optimal targeting of the mTORC1 kinase in human cancer
Lane, H. A., & Breuleux, M. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.01.016 · Cited by 75
Interaction of E-cadherin and PTEN Regulates Morphogenesis and Growth Arrest in Human Mammary Epithelial Cells
Fournier, M. V., Fata, J. E., Martin, K. J., Yaswen, P., & Bissell, M. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1694 · Cited by 75
Propolis and its Active Component, Caffeic Acid Phenethyl Ester (CAPE), Modulate breast Cancer Therapeutic Targets via an Epigenetically Mediated Mechanism of Action
Wu, M. K. J. (2013) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.1000224 · Cited by 75
Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability
Lam, P. B., Burga, L. N., Wu, B. P., Hofstatter, E. W., Lu, K. P., & Wulf, G. M. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-91 · Cited by 73
An Update on Src Family of Nonreceptor Tyrosine Kinases Biology
Espada, J., & Martı́n-Pérez, J. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.09.009 · Cited by 79
Interaction of CDCP1 with HER2 Enhances HER2-Driven Tumorigenesis and Promotes Trastuzumab Resistance in Breast Cancer
Alajati, A., Guccini, I., Pinton, S., García‐Escudero, R., Bernasocchi, T., Sarti, M., Montani, E., Rinaldi, A., Montemurro, F., Catapano, C. V., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.044 · Cited by 75
Prospective Validation of HLA-DRB1*07:01 Allele Carriage As a Predictive Risk Factor for Lapatinib-Induced Liver Injury
Schaid, D. J., Spraggs, C. F., McDonnell, S. K., Parham, L. R., Cox, C. J., Ejlertsen, B., Finkelstein, D. M., Rappold, E., Curran, J., Cardon, L. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.9867 · Cited by 75
HER3/ErbB3, an emerging cancer therapeutic target
Zhang, N., Chang, Y., Rios, A. A., & An, Z. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv103 · Cited by 75
breast cancer cells
Benlimame, N., Alaoui-Jamali, M., & Davis, M. B. (2009) · Cited by 80
HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance
Nami, B., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050040 · Cited by 77
Resistance to Trastuzumab
Vivekanandhan, S., & Knutson, K. L. (2022) · Cancers · doi:10.3390/cancers14205115 · Cited by 80
BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin
Abi‐Habib, R. J., Urieto, J. O., Liu, S., Leppla, S. H., Duesbery, N. S., & Frankel, A. E. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0145 · Cited by 74
Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial
Alba, E., Albanell, J., de la Haba-Rodríguez, J., Barnadas, A., Calvo, L., Sánchez‐Rovira, P., Ramos, M., Rojo, F., Burgués, O., Carrasco, E., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.831 · Cited by 73
Trastuzumab in gastric cancer
Okines, A. F. C., & Cunningham, D. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.05.003 · Cited by 76
Extracellular matrix protein 1 regulates cell proliferation and trastuzumab resistance through activation of epidermal growth factor signaling
Lee, K., Nam, K., Oh, S., Lim, J., Kim, Y., Lee, J. W., Yu, J., Ahn, S. H., Kim, S., Noh, D., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0479-6 · Cited by 74
HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: Outlook and recent implications in nanomedical approaches
Colombo, M., Corsi, F., Foschi, D., Mazzantini, E., Mazzucchelli, S., Morasso, C., Occhipinti, E., Polito, L., Prosperi, D., Ronchi, S., et al. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.01.013 · Cited by 73
Overcoming Resistance to HER2-Directed Therapies in Breast Cancer
Schlam, I. M., Tarantino, P., & Tolaney, S. M. (2022) · Cancers · doi:10.3390/cancers14163996 · Cited by 81
The ErbB2 Signaling Network as a Target for Breast Cancer Therapy
Badache, A., & Gonçalvès, A. (2006) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-006-9009-1 · Cited by 78
Genetic deregulation of the PIK3CA oncogene in oral cancer
Murugan, A. K., Munirajan, A. K., & Tsuchida, N. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.04.005 · Cited by 73
The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene
Tormo, E., Adam‐Artigues, A., Ballester, S., Pineda, B., Zazo, S., Gónzález-Alonso, P., Albanell, J., Rovira, A., Rojo, F., Lluch, A. M., et al. (2017) · Scientific Reports · doi:10.1038/srep41309 · Cited by 73
ErbB-directed immunotherapy: Antibodies in current practice and promising new agents
Friedländer, E., Barok, M., Szöllõsi, J., & Vereb, G. (2008) · Immunology Letters · doi:10.1016/j.imlet.2007.12.001 · Cited by 72
Pi3 Kinase/Akt Pathway As A Therapeutic Target In Multiple Myeloma
Harvey, R. D., & Lonial, S. (2007) · Future Oncology · doi:10.2217/14796694.3.6.639 · Cited by 72
EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab
Gori, S., Sidoni, A., Colozza, M., Ferri, I., Mameli, M. G., Fenocchio, D., Stocchi, L., Foglietta, J., Ludovini, V., Minenza, E., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn681 · Cited by 72
Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas
Ebbesen, S. H., Scaltriti, M., Bialucha, C. U., Morse, N., Kastenhuber, E. R., Wen, H. Y., Dow, L. E., Baselga, J. M., & Lowe, S. W. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1523693113 · Cited by 73
Gene Expression and miRNAs Profiling: Function and Regulation in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Sareyeldin, R. M., Gupta, I., Al‐Hashimi, I., Al-Thawadi, H., Farsi, H. F. A., Vranić, S., & Moustafa, A. A. (2019) · Cancers · doi:10.3390/cancers11050646 · Cited by 76
A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells
Raja, S. M., Clubb, R. J., Bhattacharyya, M., Dimri, M., Cheng, H., Pan, W., Ortega-Cava, C. F., Reddi, A. L., Naramura, M., Band, V., et al. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.10.6585 · Cited by 71
Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells
Joshi, J. P., Brown, N. E., Griner, S. E., & Nahta, R. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.07.082 · Cited by 71
PI3K in cancer–stroma interactions: bad in seed and ugly in soil
Hirsch, E., Ciraolo, E., Franco, I., Ghigo, A., & Martini, M. (2013) · Oncogene · doi:10.1038/onc.2013.265 · Cited by 70
Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells
Esparı́s-Ogando, A., Ocaña, A., Barrueco, R. R., Ferreira, L., Borges, J., & Pandiella, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn406 · Cited by 71
The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans
Carrasco, D. R., Fenton, T. R., Sukhdeo, K., Protopopova, M., Enos, M., You, M. J., Divicio, D., Nogueira, C., Stommel, J. M., Pinkus, G. S., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.028 · Cited by 69
Spontaneous Epithelial-Mesenchymal Transition and Resistance to HER-2-Targeted Therapies in HER-2-Positive Luminal Breast Cancer
Lesniak, D. M., Sabri, S., Xu, Y., Graham, K., Bhatnagar, P. K., Suresh, M. R., & Abdulkarim, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071987 · Cited by 69
Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing
Kute, T. E., Savage, L., Stehle, J., Kim-Shapiro, J. W., Blanks, M. J., Wood, J. C. S., & Vaughn, J. P. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0700-0 · Cited by 69

Authors: Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., Hortobagyi, G. N., Hung, M.-C., & Yu, D.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
Ionis Pharmaceuticals (United States) (US)
Corresponding author: Yu, Dihua
ORCID: Lan, Keng-Hsueh
Zhou, Xiaoyan
Tan, Ming
Esteva, Francisco J.
Li, Ping
Monia, Brett P.
Hung, Mien-Chie
Yu, Dihua
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2004-08
Volume: 6
Issue: 2
Pages: 117-127
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2004.06.022
OpenAlex: W2059411043
Cited by: 1,858
References: 70
Citations by year: 2026: 19 · 2025: 29 · 2024: 35 · 2023: 82 · 2022: 52 · 2021: 50 · 2020: 60 · 2019: 56 · 2018: 66 · 2017: 68 · 2016: 88 · 2015: 109 · 2014: 119 · 2013: 125 · 2012: 123
FWCI: 43.34
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 3272 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5r01ca060488-09)
National Cancer Institute (P01CA099031, 2R01-CA60488, P30CA016672)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: PTEN, trastuzumab, trastuzumab resistance, ERBB2, HER2-positive breast cancer, Src kinase inhibition, PI3K inhibitors, predictive biomarkers, antisense oligonucleotides
MeSH terms: Trastuzumab, Phosphoinositide-3 Kinase Inhibitors, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Enzyme Activation, Enzyme Inhibitors, Female, Humans, Mice, Nude, Neoplasm Transplantation, Phosphoric Monoester Hydrolases, Proto-Oncogene Proteins, Genes, Tumor Suppressor, Oligonucleotides, Antisense, Protein Serine-Threonine Kinases, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, src-Family Kinases, Phosphatidylinositol 3-Kinases, Tumor Suppressor Proteins, Cell Line, Tumor, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase, Mice, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks